Table 5 Mean (and 95%CI) K10, and PHQ-9 scores at Baseline and 3-months and 6-months for sub-analyses by symptom severity

K10 > =25

Baseline

23

29.6 (26.6–32.5)

26

31.9 (29.1–34.7)

12

31.8 (27.7–35.8)

3-months

21

26.8 (23.7–29.8)

24

26.1 (23.7–29.0)

10

25.6 (21.2–30.0)

6-months

20

22.7 (19.6–25.9)

24

23.7 (20.8–26.5)

9

27.5 (22.9–32.1)

K10 < 25

Baseline

39

16.6 (14.5–18.6)

35

17.3 (15.1–19.6)

21

17.0 (14.1–19.9)

3-months

37

19.3 (17.3–21.4)

35

17.3 (15.1–19.6)

20

20.9 (17.9–23.8)

6-months

36

19.0 (16.9–21.1)

33

17.2 (14.9–19.5)

21

18.3 (15.4–21.2)

PHQ-9 > =10

Baseline

22

14.1 (12.1–16.1)

28

14.1 (12.4–15.9)

13

12.3 (9.6–15.1)

3-months

21

10.0 (8.0–12.1)

27

10.6 (8.8–12.4)

11

13.6 (10.8–16.5)

6-months

20

9.4 (7.3–11.5)

27

11.0 (9.1–12.8)

10

13.7 (10.8–16.7)

PHQ-9 < 10

Baseline

40

5.3 (4.1–6.4)

33

4.8 (3.5–6.0)

20

4.9 (3.3–6.5)

3-months

37

7.3 (6.1–8.5)

32

4.8 (3.6–6.1)

19

5.7 (4.1–7.3)

6-months

36

6.8 (5.6–8.0)

30

4.7 (3.4–6.0)

20

5.0 (3.4–6.5)